Glycoheal G 1001 Tablet SR is a combination oral hypoglycemic agent containing Glimepiride 1mg and Metformin 1000mg, formulated for sustained release to provide effective glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, improving peripheral insulin sensitivity, and enhancing glucose uptake by muscle tissues. The sustained-release formulation ensures a gradual release of active ingredients, promoting better tolerability and adherence by minimizing gastrointestinal side effects commonly associated with metformin. Glycoheal G 1001 Tablet SR is indicated for use as monotherapy or in combination with other antidiabetic agents when diet and exercise alone do not achieve adequate glycemic control. It is essential to monitor blood glucose levels regularly and adjust dosage based on therapeutic response and patient tolerance. Caution is advised in patients with renal or hepatic impairment, and contraindications include diabetic ketoacidosis and conditions predisposing to hypoxia. This combination offers a balanced approach by targeting multiple pathophysiological defects in type 2 diabetes, thereby improving glycemic parameters and reducing the risk of diabetes-related complications.